Management of gout: beyond allopurinol

被引：5
|
作者：
McGill, N. W. [1 ]
机构：
[1] Royal Prince Alfred Hosp, Dept Rheumatol, Sydney, NSW 2071, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2010年 / 40卷 / 08期
关键词：
rheumatology; gout; allopurinol; febuxostat; SERUM URIC-ACID; TOPHACEOUS GOUT; SYNOVIAL-FLUID; RENAL-FUNCTION; INCIDENT GOUT; ADVERSE EVENTS; RISK; URATE; MEN; HYPERURICEMIA;
D O I：
10.1111/j.1445-5994.2010.02293.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The basic concepts of the pathogenesis and management of gout have not altered for many years. Monosodium urate monohydrate crystals drive the disease and identification of these crystals is required for certain diagnosis. In contrast, our understanding of the mediators of gouty inflammation, the appropriate target serum urate concentration during treatment, the drugs available and the best ways to use those drugs have all advanced in recent years and will be the focus of this review.
引用
收藏
页码：545 / 553
页数：9
相关论文
共 50 条
  • [21] Comparison between Allopurinol and Febuxostat in management of gout patients - a prospective study
    Singal, K. K.
    Goyal, S.
    Gupta, P.
    Aggawal, B. K.
    BANGLADESH JOURNAL OF MEDICAL SCIENCE, 2011, 10 (04): : 257 - 259
  • [22] WITHDRAWAL OF ALLOPURINOL IN PATIENTS WITH GOUT
    LOEBL, WY
    SCOTT, JT
    ANNALS OF THE RHEUMATIC DISEASES, 1974, 33 (04) : 304 - 307
  • [23] Febuxostat or Allopurinol in Patients with Gout Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)
    Alten, R.
    Mischkewitz, M.
    Nitschmann, S.
    INTERNIST, 2020, 61 (05): : 530 - 532
  • [24] Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis
    Jutkowitz, Eric
    Alarid-Escudero, Fernando
    Choi, Hyon K.
    Kuntz, Karen M.
    Jalal, Hawre
    PHARMACOECONOMICS, 2017, 35 (10) : 1073 - 1085
  • [25] Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis
    Eric Jutkowitz
    Fernando Alarid-Escudero
    Hyon K. Choi
    Karen M. Kuntz
    Hawre Jalal
    PharmacoEconomics, 2017, 35 : 1073 - 1085
  • [26] PREDICTORS OF ALLOPURINOL ADHERENCE IN PATIENTS WITH GOUT
    Singh, J. A.
    VALUE IN HEALTH, 2015, 18 (03) : A249 - A249
  • [27] ALLOPURINOL THERAPY OF GOUT WITH RENAL COMPLICATIONS
    SJOBERG, KH
    ANNALS OF THE RHEUMATIC DISEASES, 1966, 25 (6S) : 688 - &
  • [28] Febuxostat equals allopurinol for gout prophylaxis
    不详
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2006, 73 (03) : 214 - 214
  • [29] Allopurinol use and prevention of gout attack
    Lai, Shih-Wei
    Kuo, Yu-Hung
    Liao, Kuan-Fu
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (01) : 145 - 145
  • [30] EVALUATION OF ALLOPURINOL USE IN PATIENTS WITH GOUT
    ZELL, SC
    CARMICHAEL, JM
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1989, 46 (09): : 1813 - 1816
12345